Zogenix, Inc. Names Founding Management Team
HAYWARD and SAN DIEGO, CA (August 28, 2006) Zogenix, Inc. is a privately held specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. In conjunction with today’s separate announcement of the company’s $60 million Series A financing, Zogenix named its founding management team. The founding members are:
- Cam L. Garner, Chairman of the Board of Directors;
- Roger L. Hawley, Chief Executive Officer;
- Stephen J. Farr, Ph.D., President and Chief Operating Officer;
- Jonathan Rigby, Vice President of Business Development;
- Bret E. Megargel, Vice President of Corporate Development; and
- John J. Turanin, Vice President of Operations.
Cam L. Garner, a founder and Chairman, has more than 30 years relevant industry experience, including leading the formation and successful growth of Dura Pharmaceuticals, Inc., which was acquired by Elan Corporation, plc in 2000 for $1.8 billion. He has recently formed specialty pharmaceutical companies Verus Pharmaceuticals, Inc. and Cadence Pharmaceuticals, Inc. Mr. Garner serves as Chairman and CEO of Verus and Chairman of Cadence. In 1998, Mr. Garner founded and served as Chairman of DJ Pharma, which was sold to Biovail in 2000. In 2001, he founded and served as Chairman of Xcel Pharmaceuticals, which was sold to Valeant in 2005. Currently, he is Chairman of Favrille, Inc. (NASDAQ: FVRL) and serves on the board of numerous companies, including Pharmion Corporation (NASDAQ: PHRM), Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), SkinMedica, Inc., and Aegis Therapeutics, LLC.
Roger L. Hawley joins the founding team of Zogenix as Chief Executive Officer with over 19 years of distinguished commercial pharmaceutical experience having most recently served as Executive Vice President, Commercial and Technical Operations for InterMune (NASDAQ: INTM) since 2003. Prior to joining InterMune, Mr. Hawley held senior executive level commercial roles with Prometheus Laboratories Inc., Elan Pharmaceuticals, Inc. (NYSE: ELN), and GlaxoSmithKline (NYSE: GSK), where he ended his fourteen-year career as Vice President of Sales — CNS/ GI Division in 2001. During his career, Mr. Hawley has had the unique opportunity to participate in the launch and commercialization of three of the currently marketed triptan migraine therapies as well as other CNS products. Currently he serves on the board of Targeted Genetics (NASDAQ: TGEN) and Alios Biopharma, Inc., a private biotechnology company.
Stephen J. Farr, Ph.D. brings over 20 years of drug delivery science and drug/ device product development to his founding role of President and Chief Operating Officer. Dr. Farr most recently served as Senior Vice President and Chief Scientific Officer of Aradigm, Corp. (NASDAQ: ARDM), where he served as scientific director for Aradigm’s inhaled insulin program, and was technical director of the Intraject® program. While at Aradigm, Dr. Farr played a key leadership role in developing sumatriptan Intraject® to its current advanced stage of technical development.
Mr. Garner, Mr. Hawley, and Dr. Farr are joined by founding team members Jonathan Rigby, Bret E. Megargel, and John J. Turanin. Mr. Rigby joins Zogenix with over 16 years of pharmaceutical experience, most recently serving as Vice President of Business Development for Aradigm, Corp., where he led the original acquisition and subsequent strategic development of Intraject®. Mr. Rigby also serves as Vice Chair of the Association of Needle Free Injection Manufacturers.
Mr. Megargel has over 15 years of related healthcare experience, having most recently served as Vice President/General Manager for Planet Technologies, Inc., and Vice President, Business Development for Avera Pharmaceuticals, Inc.
Mr. Turanin adds over 20 years of pharmaceutical and medical device development experience, having most recently served as Vice President, Corporate Planning, and Program Management at Aradigm, Corp., where he led several product development programs, including sumatriptan Intraject®.
Intraject is a registered trademark of Zogenix, Inc.
Historical Information: The press releases are included on this web site for historical purposes only. The information contained in these press releases should be considered accurate only as of the date of the relevant press release. This information may change over time. Visitors to this web site should not assume that the information contained in these press releases remains accurate at a later time. Except as required by law, we undertake no obligation to update, revise or supplement any of the information contained in these press releases.
